ArticleFrontiers in pharmacology2026
Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report.
Yalin He et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.